Alkermes Plc
NASDAQ:ALKS
Alkermes Plc
NASDAQ:ALKS
Price:
24.35 USD
2.05%
Updated:
May 3, 2024
Alkermes Plc
Revenue
|
Alkermes Plc
Revenue Peer Comparison
Comparables:
AMRN
PRTA
M
MURA
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Revenue
$1.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Revenue
$306.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
6%
|
CAGR 10-Years
28%
|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Revenue
$91.4m
|
CAGR 3-Years
367%
|
CAGR 5-Years
147%
|
CAGR 10-Years
61%
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Alkermes Plc
Revenue Breakdown
Breakdown by Geography
Alkermes Plc
Alkermes Plc
|
Total Revenue:
1.7B
USD
|
|
United States:
1.5B
USD
|
|
Foreign Country Excluding Specified Country:
170.3m
USD
|
|
Ireland:
1.2m
USD
|
Breakdown by Segments
Alkermes Plc
Alkermes Plc
|
Total Revenue:
1.7B
USD
|
|
Product:
920m
USD
|
|
Vivitrol:
400.4m
USD
|
|
Aristada And Aristada Initio:
327.7m
USD
|
|
L Y B A L V I:
191.9m
USD
|
See Also
What is Alkermes Plc's Revenue?
Revenue
1.7B
USD
1.7B
USD
Based on the financial report for Dec 31, 2023, Alkermes Plc's Revenue amounts to 1.7B USD.
What is Alkermes Plc's Revenue growth rate?
Revenue CAGR 10Y
11%
11%
Over the last year, the Revenue growth was 50%. The average annual Revenue growth rates for Alkermes Plc have been 17% over the past three years , 9% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
